CompuGroup Medical SE KGaA 将来の成長

Future 基準チェック /36

CompuGroup Medical SE KGaA利益と収益がそれぞれ年間30.1%と1.9%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に12.3% 29.7%なると予測されています。

主要情報

30.1%

収益成長率

29.7%

EPS成長率

Healthcare Services 収益成長	32.2%
収益成長率	1.9%
将来の株主資本利益率	12.3%
アナリストカバレッジ	Good
最終更新日	03 Feb 2025

今後の成長に関する最新情報

CompuGroup Medical SE & Co. KGaA (ETR:COP) Just Reported Earnings, And Analysts Cut Their Target Price

Jul 18

Earnings Release: Here's Why Analysts Cut Their CompuGroup Medical SE & Co. KGaA (ETR:COP) Price Target To €43.20

May 11

Recent updates

Is It Too Late To Consider Buying CompuGroup Medical SE & Co. KGaA (ETR:COP)?

Nov 26

CompuGroup Medical SE & Co. KGaA's (ETR:COP) Popularity With Investors Is Clear

Nov 08

Here's What's Concerning About CompuGroup Medical SE KGaA's (ETR:COP) Returns On Capital

Sep 06

Here's Why CompuGroup Medical SE KGaA (ETR:COP) Has A Meaningful Debt Burden

Aug 20

What You Can Learn From CompuGroup Medical SE & Co. KGaA's (ETR:COP) P/E After Its 34% Share Price Crash

Aug 04

CompuGroup Medical SE & Co. KGaA (ETR:COP) Just Reported Earnings, And Analysts Cut Their Target Price

Jul 18

Is It Too Late To Consider Buying CompuGroup Medical SE & Co. KGaA (ETR:COP)?

Jul 15

Investors Still Waiting For A Pull Back In CompuGroup Medical SE & Co. KGaA (ETR:COP)

Jun 11

The Returns On Capital At CompuGroup Medical SE KGaA (ETR:COP) Don't Inspire Confidence

May 24

Earnings Release: Here's Why Analysts Cut Their CompuGroup Medical SE & Co. KGaA (ETR:COP) Price Target To €43.20

May 11

CompuGroup Medical SE KGaA (ETR:COP) Will Pay A Larger Dividend Than Last Year At €1.00

Apr 27

CompuGroup Medical SE KGaA's (ETR:COP) Upcoming Dividend Will Be Larger Than Last Year's

Apr 12

We Think CompuGroup Medical SE KGaA (ETR:COP) Can Stay On Top Of Its Debt

Mar 20

CompuGroup Medical SE & Co. KGaA (ETR:COP) Shares Could Be 49% Below Their Intrinsic Value Estimate

Feb 08

Investors Interested In CompuGroup Medical SE & Co. KGaA's (ETR:COP) Earnings

Jan 25

Is It Time To Consider Buying CompuGroup Medical SE & Co. KGaA (ETR:COP)?

Jan 12

The Returns On Capital At CompuGroup Medical SE KGaA (ETR:COP) Don't Inspire Confidence

Dec 28

At €46.82, Is CompuGroup Medical SE & Co. KGaA (ETR:COP) Worth Looking At Closely?

Jun 24

CompuGroup Medical SE KGaA (ETR:COP) Is Reinvesting At Lower Rates Of Return

May 27

CompuGroup Medical SE KGaA (ETR:COP) Has Announced A Dividend Of €0.50

May 11

Is CompuGroup Medical SE & Co. KGaA (ETR:COP) Trading At A 32% Discount?

May 06

We Think CompuGroup Medical SE KGaA (ETR:COP) Can Stay On Top Of Its Debt

Apr 06

What Does CompuGroup Medical SE & Co. KGaA's (ETR:COP) Share Price Indicate?

Mar 07

Be Wary Of CompuGroup Medical SE KGaA (ETR:COP) And Its Returns On Capital

Feb 06

An Intrinsic Calculation For CompuGroup Medical SE & Co. KGaA (ETR:COP) Suggests It's 28% Undervalued

Jan 21

These 4 Measures Indicate That CompuGroup Medical SE KGaA (ETR:COP) Is Using Debt Reasonably Well

Jan 05

Is Now An Opportune Moment To Examine CompuGroup Medical SE & Co. KGaA (ETR:COP)?

Dec 06

業績と収益の成長予測

XTRA:COP - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2027	1,240	N/A	N/A	N/A	2
12/31/2026	1,224	69	88	182	9
12/31/2025	1,192	60	79	171	9
12/31/2024	1,163	54	39	131	9
9/30/2024	1,189	25	77	148	N/A
6/30/2024	1,193	32	68	138	N/A
3/31/2024	1,220	50	93	162	N/A
12/31/2023	1,228	46	112	180	N/A
9/30/2023	1,247	76	135	201	N/A
6/30/2023	1,249	89	123	193	N/A
3/31/2023	1,214	70	82	157	N/A
12/31/2022	1,175	73	69	145	N/A
9/30/2022	1,127	72	45	122	N/A
6/30/2022	1,116	71	58	140	N/A
3/31/2022	1,088	76	88	165	N/A
12/31/2021	1,063	69	94	165	N/A
9/30/2021	1,021	66	88	155	N/A
6/30/2021	975	72	111	166	N/A
3/31/2021	915	71	113	168	N/A
12/31/2020	869	73	94	150	N/A
9/30/2020	833	77	86	128	N/A
6/30/2020	779	60	34	80	N/A
3/31/2020	781	58	60	107	N/A
12/31/2019	770	66	67	110	N/A
9/30/2019	757	87	83	137	N/A
6/30/2019	742	86	123	170	N/A
3/31/2019	747	97	109	155	N/A
12/31/2018	736	96	97	136	N/A
9/30/2018	707	65	73	112	N/A
6/30/2018	678	52	N/A	109	N/A
3/31/2018	624	39	N/A	101	N/A
12/31/2017	599	31	N/A	86	N/A
9/30/2017	586	41	N/A	89	N/A
6/30/2017	583	46	N/A	80	N/A
3/31/2017	578	47	N/A	78	N/A
12/31/2016	571	45	N/A	68	N/A
9/30/2016	562	41	N/A	67	N/A
6/30/2016	553	36	N/A	68	N/A
3/31/2016	556	27	N/A	55	N/A
12/31/2015	553	38	N/A	73	N/A
9/30/2015	548	34	N/A	41	N/A
6/30/2015	547	40	N/A	31	N/A
3/31/2015	535	42	N/A	35	N/A
12/31/2014	525	26	N/A	32	N/A
9/30/2014	511	29	N/A	55	N/A
6/30/2014	496	24	N/A	51	N/A
3/31/2014	479	18	N/A	45	N/A

アナリストによる今後の成長予測

収入対貯蓄率: COPの予測収益成長率 (年間30.1% ) は貯蓄率 ( 1.1% ) を上回っています。

収益対市場: COPの収益 ( 30.1% ) はGerman市場 ( 19.8% ) よりも速いペースで成長すると予測されています。

高成長収益: COPの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: COPの収益 ( 1.9% ) German市場 ( 5.9% ) よりも低い成長が予測されています。

高い収益成長: COPの収益 ( 1.9% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: COPの自己資本利益率は、3年後には低くなると予測されています ( 12.3 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/02/15 22:58
終値	2025/02/14 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

CompuGroup Medical SE & Co. KGaA 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。17

アナリスト	機関
Knut Woller	Baader Helvea Equity Research
Gerhard Schwarz	Baader Helvea Equity Research
Gunnar Cohrs	Berenberg

CompuGroup Medical SE KGaA 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Price target decreased by 19% to €21.75

CompuGroup Medical SE & Co. KGaA (ETR:COP) Just Reported Earnings, And Analysts Cut Their Target Price

Consensus EPS estimates fall by 32%

Price target decreased by 13% to €37.80

Earnings Release: Here's Why Analysts Cut Their CompuGroup Medical SE & Co. KGaA (ETR:COP) Price Target To €43.20

Price target decreased by 8.6% to €47.55

Recent updates

CompuGroup Medical SE & Co. KGaA to Report Q1, 2025 Results on Apr 30, 2025

New minor risk - Share price stability

Price target decreased by 19% to €21.75

Is It Too Late To Consider Buying CompuGroup Medical SE & Co. KGaA (ETR:COP)?

CompuGroup Medical SE & Co. KGaA to Report Q2, 2025 Results on Jul 31, 2025

Third quarter 2024 earnings released: EPS: €0.17 (vs €0.30 in 3Q 2023)

CompuGroup Medical SE & Co. KGaA's (ETR:COP) Popularity With Investors Is Clear

Here's What's Concerning About CompuGroup Medical SE KGaA's (ETR:COP) Returns On Capital

Here's Why CompuGroup Medical SE KGaA (ETR:COP) Has A Meaningful Debt Burden

What You Can Learn From CompuGroup Medical SE & Co. KGaA's (ETR:COP) P/E After Its 34% Share Price Crash

CompuGroup Medical SE & Co. KGaA Announces CEO Changes

CompuGroup Medical SE & Co. KGaA (ETR:COP) Just Reported Earnings, And Analysts Cut Their Target Price

New major risk - Financial position

Is It Too Late To Consider Buying CompuGroup Medical SE & Co. KGaA (ETR:COP)?

Consensus EPS estimates fall by 32%

Price target decreased by 13% to €37.80

Investor sentiment deteriorates as stock falls 31%

CompuGroup Medical SE & Co. KGaA (XTRA:COP) acquired AmbulApps GmbH.

Investors Still Waiting For A Pull Back In CompuGroup Medical SE & Co. KGaA (ETR:COP)

The Returns On Capital At CompuGroup Medical SE KGaA (ETR:COP) Don't Inspire Confidence

Upcoming dividend of €1.00 per share

Earnings Release: Here's Why Analysts Cut Their CompuGroup Medical SE & Co. KGaA (ETR:COP) Price Target To €43.20

First quarter 2024 earnings released: EPS: €0.35 (vs €0.28 in 1Q 2023)

CompuGroup Medical SE KGaA (ETR:COP) Will Pay A Larger Dividend Than Last Year At €1.00

Now 20% overvalued

CompuGroup Medical SE KGaA's (ETR:COP) Upcoming Dividend Will Be Larger Than Last Year's

CompuGroup Medical SE & Co. KGaA Proposes Dividend for the Year 2023

Price target decreased by 8.6% to €47.55

Full year 2023 earnings: EPS misses analyst expectations

CompuGroup Medical SE & Co. KGaA Announces Chief Executive Officer for the US Changes

We Think CompuGroup Medical SE KGaA (ETR:COP) Can Stay On Top Of Its Debt

Dividend of €1.00 announced

Now 21% undervalued after recent price drop

Consensus EPS estimates fall by 16%

Price target decreased by 9.8% to €48.75

New minor risk - Share price stability

Full year 2023 earnings released: EPS: €0.88 (vs €1.41 in FY 2022)

CompuGroup Medical SE & Co. KGaA (ETR:COP) Shares Could Be 49% Below Their Intrinsic Value Estimate

Investor sentiment deteriorates as stock falls 18%

Investors Interested In CompuGroup Medical SE & Co. KGaA's (ETR:COP) Earnings

Is It Time To Consider Buying CompuGroup Medical SE & Co. KGaA (ETR:COP)?

The Returns On Capital At CompuGroup Medical SE KGaA (ETR:COP) Don't Inspire Confidence

We Think CompuGroup Medical SE KGaA (ETR:COP) Can Stay On Top Of Its Debt

Third quarter 2023 earnings released: EPS: €0.31 (vs €0.56 in 3Q 2022)

CompuGroup Medical SE & Co. KGaA to Report Q3, 2024 Results on Nov 07, 2024

Is CompuGroup Medical SE & Co. KGaA (ETR:COP) Potentially Undervalued?

CompuGroup Medical SE & Co. KGaA Appoints Daniela Hommel as Chief Financial Officer, Effective March 2024

CompuGroup Medical SE KGaA (ETR:COP) Could Be Struggling To Allocate Capital

Do CompuGroup Medical SE KGaA's (ETR:COP) Earnings Warrant Your Attention?

Is CompuGroup Medical SE & Co. KGaA (ETR:COP) Trading At A 33% Discount?

Second quarter 2023 earnings released: EPS: €0.60 (vs €0.23 in 2Q 2022)

Here's Why CompuGroup Medical SE KGaA (ETR:COP) Can Manage Its Debt Responsibly

At €46.82, Is CompuGroup Medical SE & Co. KGaA (ETR:COP) Worth Looking At Closely?

CompuGroup Medical SE KGaA (ETR:COP) Is Reinvesting At Lower Rates Of Return

Compugroup Medical Se & Co. KGaa Appoints Michael Rauch as CEO

Upcoming dividend of €0.50 per share at 1.0% yield

CompuGroup Medical SE KGaA (ETR:COP) Has Announced A Dividend Of €0.50

CompuGroup Medical SE & Co. KGaA Confirms Revenue Guidance for 2023

First quarter 2023 earnings released: EPS: €0.28 (vs €0.35 in 1Q 2022)

Is CompuGroup Medical SE & Co. KGaA (ETR:COP) Trading At A 32% Discount?

We Think CompuGroup Medical SE KGaA (ETR:COP) Can Stay On Top Of Its Debt

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

What Does CompuGroup Medical SE & Co. KGaA's (ETR:COP) Share Price Indicate?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CompuGroup Medical SE & Co. KGaA to Report Q4, 2022 Results on Feb 09, 2023

Be Wary Of CompuGroup Medical SE KGaA (ETR:COP) And Its Returns On Capital

An Intrinsic Calculation For CompuGroup Medical SE & Co. KGaA (ETR:COP) Suggests It's 28% Undervalued

These 4 Measures Indicate That CompuGroup Medical SE KGaA (ETR:COP) Is Using Debt Reasonably Well

CompuGroup Medical SE & Co. KGaA to Report First Half, 2023 Results on Aug 10, 2023